Back to top
more

Cerevel Therapeutics (CERE)

(Delayed Data from NSDQ)

$41.90 USD

41.90
629,646

-0.09 (-0.21%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $41.89 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio

AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.

AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B

AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.

Wall Street Analysts Think Cerevel Therapeutics Holdings, Inc. (CERE) Could Surge 27.31%: Read This Before Placing a Bet

The mean of analysts' price targets for Cerevel Therapeutics Holdings, Inc. (CERE) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Why Cerevel Therapeutics (CERE) Might Surprise This Earnings Season

Cerevel Therapeutics (CERE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks

Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks

Shrabana Mukherjee headshot

New Analyst Coverage Puts Spotlight on These 4 Stocks

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like HIBB, ITGR, CERE and ATEN.

Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I

Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.

Company News for Jun 30, 2021

Companies in the news are: EPAC, CERE, PLBY, MRNA